Abeona Therapeutics Inc. (ABEO)
ABEO moved a median of +0.09% 30 minutes after news, and -0.34% by the close. How ABEO actually reacts to news — the realized, point-in-time move the market made, measured across 438 labeled events over the last three years with zero look-ahead.
ABEO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 44% | 432 |
| 30-min | +0.09% | 51% | 434 |
| 60-min | -0.36% | 45% | 434 |
| to close | -0.34% | 44% | 432 |
| Middle 50% of ABEO reactions | -1.31% to +1.21% |
|---|---|
| Median reaction (30-min) | +0.09% |
| Measured reactions | 438 |
Half of all Abeona Therapeutics Inc. news events land between -1.31% and +1.21% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ABEO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 16 | -0.39% | 50% | -1.33% |
| Analyst downgrades | 13 | -0.42% | 31% | -4.04% |
| Coverage initiations | 15 | -0.47% | 13% | -1.31% |
| Rating reiterations | 41 | +0.53% | 59% | +0.52% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how ABEO ranks against every other measured name →
That’s how ABEO usually reacts — get an email when it moves on news →Email me when ABEO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ABEO's baseline. Nothing else.
Recent ABEO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.69% | -1.18% | |
| Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA) | Press release | GlobeNewswire | -2.74% | -4.62% | |
| Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN® | Press release | GlobeNewswire | -0.54% | -2.54% | |
| Form 8-K ABEONA THERAPEUTICS INC. For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | +0.38% | +2.72% | |
| ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law | Press release | Business Wire | +0.24% | -0.34% | |
| Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.00% | -0.50% | |
| Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.34% | +3.10% | |
| Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update | Press release | GlobeNewswire | +5.91% | +4.19% | |
| Form 10-Q ABEONA THERAPEUTICS INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +5.91% | +4.19% | |
| Form 8-K ABEONA THERAPEUTICS INC. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +5.91% | +4.19% | |
| Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 | Press release | GlobeNewswire | +2.06% | +1.77% | |
| CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN® | Press release | GlobeNewswire | +0.92% | +4.92% | |
| Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.71% | -0.93% | |
| Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN® | Press release | GlobeNewswire | -1.85% | +0.77% | |
| Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.27% | -1.95% | |
| Form S-8 ABEONA THERAPEUTICS INC. | SEC filing · Form S-8 | SEC EDGAR | +0.36% | +1.07% | |
| Form 8-K ABEONA THERAPEUTICS INC. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +0.18% | +0.00% | |
| Form 8-K ABEONA THERAPEUTICS INC. For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | +0.36% | +2.35% | |
| Form 8-K ABEONA THERAPEUTICS INC. For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -0.75% | +3.36% | |
| Form 8-K ABEONA THERAPEUTICS INC. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +0.35% | +2.29% | |
| Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.27% | -1.57% | |
| Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.44% | +0.00% | |
| Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update | Press release | GlobeNewswire | -1.29% | -1.72% | |
| Form 10-Q ABEONA THERAPEUTICS INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.29% | -1.72% | |
| Form 8-K ABEONA THERAPEUTICS INC. For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -1.29% | -1.72% | |
| Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN® | Press release | GlobeNewswire | -0.25% | -1.51% | |
| Abeona Therapeutics® Announces Date of First Quarter Financial Results | Press release | GlobeNewswire | +1.92% | +9.78% | |
| Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | — | — | |
| Form DEFA14A ABEONA THERAPEUTICS INC. | SEC filing · Form DEFA14A | SEC EDGAR | -0.83% | -3.16% | |
| Form ARS ABEONA THERAPEUTICS INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.47% | +0.75% | |
| Form DEF 14A ABEONA THERAPEUTICS INC. For: Apr 27 | SEC filing · Form DEF | SEC EDGAR | +0.47% | +0.75% | |
| Form PRE 14A ABEONA THERAPEUTICS INC. For: Apr 17 | SEC filing · Form PRE | SEC EDGAR | -0.27% | +0.00% | |
| Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors | Press release | GlobeNewswire | +0.00% | +0.94% | |
| Form 8-K ABEONA THERAPEUTICS INC. For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.94% | |
| Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.31% | -2.26% | |
| Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York | Press release | GlobeNewswire | +0.89% | +7.11% | |
| Form 8-K ABEONA THERAPEUTICS INC. For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | -1.11% | -1.78% | |
| Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates | Press release | GlobeNewswire | -4.39% | -0.42% | |
| Form 10-K ABEONA THERAPEUTICS INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.39% | -0.42% | |
| Form 8-K ABEONA THERAPEUTICS INC. For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | -4.39% | -0.42% | |
| Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch | Press release | GlobeNewswire | +4.21% | +8.63% | |
| Form 8-K ABEONA THERAPEUTICS INC. For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | +4.21% | +8.63% | |
| Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference | Press release | GlobeNewswire | -0.60% | -0.60% | |
| Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.69% | +0.49% | |
| Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.58% | +1.54% | |
| Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer | Press release | GlobeNewswire | -0.93% | -5.75% | |
| Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas | Press release | GlobeNewswire | +0.09% | +0.91% | |
| Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy | Press release | GlobeNewswire | -1.87% | +0.79% | |
| Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.20% | -4.21% | |
| Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates | Press release | GlobeNewswire | +10.00% | +7.39% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ABEO section they belong to.
Where else ABEO is measured.
ABEO earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Pacific Biosciences of California, Inc. (PACB) | 440 | -0.29% | 44% |
| EyePoint, Inc. (EYPT) | 439 | -0.25% | 46% |
| KalVista Pharmaceuticals, Inc. (KALV) | 438 | 0.00% | 50% |
| Zymeworks Inc. (ZYME) | 438 | 0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Abeona Therapeutics Inc.'s median reaction calculated?
Every labeled ABEO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 438 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of ABEO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ABEO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.